Granted Patent
B2
US 12,582,625 · App. 18/999,227 · Granted Mar 24, 2026
Methods for treating neuroblastoma
Inventors:
Eugene Gerner (Tucson, AZ); Elizabeth Bruckheimer (Tucson, AZ); Giselle Saulnier Sholler (Hershey, PA)
A61K31/198A61K31/192A61K31/203A61K31/415A61K31/616A61K31/69A61K31/7048A61K39/395A61K39/39558A61K45/06A61P35/00C07K16/3084C12Q1/6886A61K2039/505A61K2300/00C12Q2600/106C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides methods and kits a) for preventing and/or treating neuroblastoma (e.g., high-risk neuroblastoma) that is linked, in part, to high levels of ODC activity and increased cellular polyamine content, b) for predicting cancer patient survival, especially cancer patients whose cancer is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and c) for selecting treatment options for such patients based on the allelic nucleotide sequence or SNP at positions +263 and/or +316 of the ODC1 gene. The invention also provides, cancer treatment methods comprising the determination of the ODC1 genotype at the +263 and/or +316 positions, as a means to guide treatment selection, which includes, in some aspects the administration of pharmaceutically effective amounts of α-difluoromethylornithine (DFMO), either as a monotherapy or in combination with one or more other drugs. In addition, the present invention provides methods for preventing and/or treating patients that have been determined to have cancer stem cells, such as patients in cancer remission that are at risk for relapse.
Claims (46)
1 . A method for reducing the risk of relapse of neuroblastoma in a patient diagnosed with high-risk neuroblastoma, the method comprising:
orally administering to the patient a pharmaceutical composition comprising α-difluoromethylornithine (DFMO) hydrochloride monohydrate;
wherein the pharmaceutical composition is orally administered to the patient twice a day, independent of the patient's food intake;
wherein the oral administration of the pharmaceutical composition twice a day provides to the patient a total daily dose of α-difluoromethylornithine (DFMO) hydrochloride monohydrate, expressed as grams α-difluoromethylornithine (DFMO) hydrochloride monohydrate per m 2 body surface area, that is from 0.05 grams/m 2 to 5 grams/m 2 ;
wherein the patient has demonstrated at least a partial response to prior therapy and the patient's high-risk neuroblastoma is in remission; and
wherein the prior therapy comprises anti-GD2 immunotherapy.
2 . The method according to claim 1 , wherein the pharmaceutical composition is a powder.
3 . The method according to claim 1 , wherein the pharmaceutical composition is one or more tablets.
4 . The method according to claim 3 , wherein each of the one or more tablets comprises 250 mg of α-difluoromethylornithine (DFMO) hydrochloride monohydrate.
5 . The method according to claim 1 , wherein the prior therapy further comprises chemotherapy.
6 . The method according to claim 1 , wherein the patient has demonstrated at least a partial response to prior therapy by demonstrating one of the following:
(i) no evidence of neuroblastoma based on anatomical imaging and on pathological assessment of the bone marrow; or
(ii) neuroblastoma detected on anatomical imaging that is determined to be metabolically inactive by functional imaging, and no evidence of neuroblastoma in the bone marrow based on pathological assessment of the bone marrow.
7 . The method according to claim 1 , wherein the patient has demonstrated a complete response to prior therapy.
8 . The method according to claim 1 , wherein the oral administration of the pharmaceutical composition twice a day provides to the patient a total daily dose of α-difluoromethylornithine (DFMO) hydrochloride monohydrate that is from 1 gram/m 2 to 3 grams/m 2 .
9 . The method according to claim 1 , wherein the oral administration of the pharmaceutical composition twice a day provides to the patient a total daily dose of α-difluoromethylornithine (DFMO) hydrochloride monohydrate that is from 1 gram/m 2 to 2 grams/m 2 .
10 . The method according to claim 1 , wherein the amount of α-difluoromethylornithine (DFMO) hydrochloride monohydrate administered to the patient is:
250 mg α-difluoromethylornithine (DFMO) hydrochloride monohydrate twice a day, if the patient has a body surface area that is at least 0.25 m 2 and is less than 0.5 m 2 ,
500 mg α-difluoromethylornithine (DFMO) hydrochloride monohydrate twice a day, if the patient has a body surface area that is at least 0.5 m 2 and is less than 0.75 m 2 ,
750 mg α-difluoromethylornithine (DFMO) hydrochloride monohydrate twice a day, if the patient has a body surface area that is at least 0.75 m 2 and is no greater than 1.5 m 2 , and
1 gram α-difluoromethylornithine (DFMO) hydrochloride monohydrate twice a day, if the patient has a body surface area that is greater than 1.5 m 2 .
11 . A method for reducing the risk of relapse of neuroblastoma in a patient diagnosed with high-risk neuroblastoma, the method comprising:
orally administering to the patient a total daily dose of α-difluoromethylornithine (DFMO) hydrochloride monohydrate, expressed as grams α-difluoromethylornithine (DFMO) hydrochloride monohydrate per m 2 body surface area, that is from 0.05 grams/m 2 to; 5 grams/m 2 ;
wherein the patient has demonstrated at least a partial response to prior therapy and the patient's high-risk neuroblastoma is in remission; and
wherein the prior therapy comprises anti-GD2 immunotherapy.
12 . The method according to claim 11 , wherein the total daily dose of α-difluoromethylornithine (DFMO) hydrochloride monohydrate is from 1 gram/m 2 to 2 grams/m 2 .
13 . The method according to claim 12 , wherein the α-difluoromethylornithine (DFMO) hydrochloride monohydrate is orally administered to the patient in one or more tablets.
14 . The method according to claim 13 , wherein each of the one or more tablets comprises 250 mg of α-difluoromethylornithine (DFMO) hydrochloride monohydrate.
15 . The method according to claim 12 , wherein the α-difluoromethylornithine (DFMO) hydrochloride monohydrate is mixed with a liquid or with food prior to said oral administration.
16 . The method according to claim 11 , wherein the total daily dose of α-difluoromethylornithine (DFMO) hydrochloride monohydrate is orally administered to the patient in two doses of α-difluoromethylornithine (DFMO) hydrochloride monohydrate, wherein said two doses are equal to each other, each being from 0.5 grams/m 2 to 1 gram/m 2 of α-difluoromethylornithine (DFMO) hydrochloride monohydrate.
17 . The method according to claim 16 , wherein each of said two doses of α-difluoromethylornithine (DFMO) hydrochloride monohydrate is administered in one or more tablets.
18 . The method according to claim 17 , wherein the one or more tablets each provide 250 mg of α-difluoromethylornithine (DFMO) hydrochloride monohydrate.
19 . The method according to claim 17 , wherein the prior therapy further comprises chemotherapy.
20 . The method according to claim 16 , wherein the α-difluoromethylornithine (DFMO) hydrochloride monohydrate is mixed with a liquid or with food prior to said oral administration.
21 . The method according to claim 16 , wherein the prior therapy further comprises chemotherapy.
22 . The method according to claim 11 , wherein an amount of 250 mg, 500 mg, 750 mg, or 1000 mg of α-difluoromethylornithine (DFMO) hydrochloride monohydrate is administered to the patient twice a day, and wherein the prior therapy further comprises chemotherapy.
23 . The method according to claim 22 , wherein said amount of α-difluoromethylornithine (DFMO) hydrochloride monohydrate is administered in one or more tablets that each provide 250 mg of α-difluoromethylornithine (DFMO) hydrochloride monohydrate.
24 . A method for reducing the risk of relapse of neuroblastoma in a patient diagnosed with high-risk neuroblastoma, the method comprising:
orally administering to the patient a total amount of 250 mg, 500 mg, 1,000 mg, 1,500 mg, or 2,000 mg of α-difluoromethylornithine (DFMO) hydrochloride monohydrate per day; and
wherein the patient has demonstrated at least a partial response to prior therapy and the patient's high-risk neuroblastoma is in remission.
25 . The method according to claim 24 , wherein the prior therapy comprises anti-GD2 immunotherapy.
26 . The method according to claim 25 , wherein 500 mg, 1,000 mg, 1,500 mg, or 2,000 mg is the total amount of α-difluoromethylornithine (DFMO) hydrochloride monohydrate per day, and the α-difluoromethylornithine (DFMO) hydrochloride monohydrate is administered to the patient twice a day in one or more tablets.
27 . The method according to claim 26 , wherein the one or more tablets each provide 250 mg of α-difluoromethylornithine (DFMO) hydrochloride monohydrate.
28 . The method according to claim 24 , wherein 500 mg, 1,000 mg, 1,500 mg, or 2,000 mg is the total amount of α-difluoromethylornithine (DFMO) hydrochloride monohydrate per day, and 250 mg, 500 mg, 750 mg, or 1,000 mg of α-difluoromethylornithine (DFMO) hydrochloride monohydrate is administered to the patient twice a day to provide said total amount per day.
29 . The method according to claim 24 , wherein 500 mg, 1,000 mg, 1,500 mg, or 2,000 mg is the total amount of α-difluoromethylornithine (DFMO) hydrochloride monohydrate per day, and wherein for a time period of up to two years, said total amount per day is administered to the patient as 250 mg, 500 mg, 750 mg, or 1,000 mg of α-difluoromethylornithine (DFMO) hydrochloride monohydrate twice a day.
30 . The method according to claim 24 , wherein the prior therapy comprises anti-GD2 immunotherapy and chemotherapy.
Assignments (7)
SECURITY INTEREST
Recorded Jul 29, 2025
From: USWM, LLC
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 071868/0283 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 24, 2025
From: SHOLLER, GISELLE
To: UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE
Reel/Frame 071825/0377 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 24, 2025
From: UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE
To: USWM, LLC
Reel/Frame 071825/0390 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 2, 2025
From: PANBELA THERAPEUTICS, INC.; CANCER PREVENTION PHARMACEUTICALS, INC.
To: USWM, LLC
Reel/Frame 069721/0499 →
LICENSE
Recorded Jan 2, 2025
From: UNIVERSITY OF ARIZONA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 070901/0898 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 2, 2025
From: GERNER, EUGENE
To: THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA; CANCER PREVENTION PHARMACEUTICALS, INC.
Reel/Frame 069809/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 2, 2025
From: BRUCKHEIMER, ELIZABETH
To: CANCER PREVENTION PHARMACEUTICALS, INC.
Reel/Frame 069809/0853 →
Continuity (6)
Continuation
15550595
Provisional Application
62115413
· Feb 12, 2015
Provisional Application
62154804
· Apr 30, 2015
References Cited (277)
US 4309442A
· Bey
· 1982
[cited by applicant]
US 4330559A
· Bey
· 1982
[cited by applicant]
US 4413141A
· Bey
· 1983
[cited by applicant]
US 4499072A
· Sunkara
· 1985
[cited by applicant]
US 4859452A
· Ajani
· 1989
[cited by applicant]
US 4925835A
· Heston
· 1990
[cited by applicant]
US 5002879A
· Bowlin
· 1991
[cited by applicant]
US 5814625A
· Larson
· 1998
[cited by applicant]
US 5843929A
· Larson
· 1998
[cited by applicant]
US 6258845B1
· Gerner
· 2001
[cited by applicant]
US 6573290B1
· Love
· 2003
[cited by applicant]
US 6602910B2
· Levenson
· 2003
[cited by applicant]
US 6753422B2
· O'Brien
· 2004
[cited by applicant]
US 7273888B2
· Ramesh
· 2007
[cited by applicant]
US 7592319B2
· Li
· 2009
[cited by applicant]
US 8329636B2
· Gerner
· 2012
[cited by examiner]
US 9072778B2
· Bachmann
· 2015
[cited by applicant]
US 9121852B2
· Gerner
· 2015
[cited by examiner]
US 9937141B2
· Gerner
· 2018
[cited by examiner]
US 20020081611A1
· O'Brien
· 2002
[cited by applicant]
US 20020110590A1
· Shaked
· 2002
[cited by applicant]
US 20050059690A1
· Newman
· 2005
[cited by applicant]
US 20110256161A1
· Burns
· 2011
[cited by applicant]
US 20120259013A1
· Motwani
· 2012
[cited by applicant]
US 20130217743A1
· Raj
· 2013
[cited by applicant]
US 20190046484A1
· Gerner
· 2019
[cited by applicant]
US 20210378999A1
· Gerner
· 2021
[cited by applicant]
US 20240165063A1
· Gerner
· 2024
[cited by applicant]
CA 2165481A1
· 1995
[cited by applicant]
CA 2345112A1
· 2000
[cited by applicant]
EP 2438919A1
· 2012
[cited by applicant]
JP 2002509884A
· 2002
[cited by applicant]
JP 2002526468A
· 2002
[cited by applicant]
JP 2005501881A
· 2005
[cited by applicant]
JP 2007537719A
· 2007
[cited by applicant]
JP 2010505909A
· 2010
[cited by applicant]
JP 2012511052A
· 2012
[cited by applicant]
JP 2016515519A
· 2016
[cited by applicant]
WO 9825603A1
· 1998
[cited by applicant]
WO 9949859A1
· 1999
[cited by applicant]
WO 0168076A2
· 2001
[cited by applicant]
WO 0215895A2
· 2002
[cited by applicant]
WO 03020209A2
· 2003
[cited by applicant]
WO 2005070967A2
· 2005
[cited by applicant]
WO 2009048932A2
· 2009
[cited by applicant]
WO 2010056919A2
· 2010
[cited by applicant]
WO 2010132817A1
· 2010
[cited by applicant]
WO 2011135459A2
· 2011
[cited by applicant]
WO WO2014070767A1
· 2014
[cited by examiner]
WO 2014140072A1
· 2014
[cited by applicant]
WO 2014144763A2
· 2014
[cited by applicant]
WO WO2015195120A1
· 2015
[cited by examiner]
WO 2017075576A1
· 2017
[cited by applicant]
Lozier et al. (Oncotarget, vol. 6, No. 1, pp. 196-206, Published online Nov. 2014). (Year: 2014).
[cited by examiner]
Johansson et al. (J. of Pharmacokinetics and Pharmacodynamics, vol. 40, pp. 117-128, 2013). (Year: 2013).
[cited by examiner]
Sholler (Abstract LB-179: Phase I trial of relapsed neuroblastoma with DFMO alone and in combination with etoposide, vol. 73, Supplement 8, LB-179, Apr. 15, 2013). (Year: 2013).
[cited by examiner]
Sholler et al. (PLoS, vol. 10, No. 5, e0127246, May 2015).
[cited by examiner]
Jeter et al. (Difluoromethylornithine: The proof is in the polyamines, Cancer Prev. Res. vol. 5, No. 12, pp. 1341-1344, 2012) (Year: 2012).
[cited by examiner]
Gerner et al., “Gastrointestinal tissue polyamine contents of patients with Barrett's esophagus treated with alpha-difluoromethylornithine,” Cancer Epidemiol. Biomarkers Prev., 3:325-330, dated 1994.
[cited by applicant]
Gerner, “Impact of dietary amino acids and polyamines on intestinal carcinogenesis and chemoprevention in mouse models”, Biochemical Society Transactions, 35(2):322-325, dated 2007.
[cited by applicant]
Gerner, E. W., et al. “Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention.” Amino acids 33.2: 189-195, dated 2007.
[cited by applicant]
Giardiello et al., “Ornithine decarboxylase and polyamines in familial adenomatous polyposis,” Cancer Res., (57):199-201, dated 1997.
[cited by applicant]
Greenberg et al., “Reduced risk of large bowel adenomas among aspirin users,” J. Natl. Cancer Inst., 85:912-916, dated 1993.
[cited by applicant]
Guo et al., “Functional analysis of human ornithine decarboxylase alleles,” Cancer Res., 60(22):6314-6317, dated 2000.
[cited by applicant]
Hanif et al., “Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway,” Biochemical Pharmacology, (52):237-245, dated …
[cited by applicant]
Hessels et al., “Microbial flora in the gastrointestinal tract abolishes cytostatic effects of a-difluoromethylornithine in vivo,” Int. J. Cancer, 43: 1155-1164, dated 1989.
[cited by applicant]
Hixson et al., “Ornithine decarboxylase and polyamines in colorectal neoplasia and mucosa,” Cancer Epidemiology Biomarkers Prev., 2:369-374, dated 1993.
[cited by applicant]
Hixson et al., “Sources of variability in measurements of ornithine decarboxylase activity and polyamine contents in colorectal mucosa,” Cancer Epidemoil. Biomarkers Prev., 3:317-323, dated 1994.
[cited by applicant]
Hogarty et al., “ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma,” Cancer Res., 68:9735-9745, dated 2008.
[cited by applicant]
Hubner et al., “Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention,” Clin. Cancer Res., 14(8):2303-9, dated 2008.
[cited by applicant]
Hughes, et al., “Polyamines reverse non-steroidal anti-inflammatory drug-induced toxicity in human colorectal cancer cells”, Biochem J, 374:481-8, dated 2003.
[cited by applicant]
Ignatenko et al., “Dietary putrescine reduces the intestinal anticarcinogenic activity of sulindac in a murine model of familial adenomatous polyposis,” Nutrition and Cancer, 56(2): 172-181, dated 2006.
[cited by applicant]
Ignatenko et al., “Role of c-Myc in intestinal tumorigenesis of the ApcMin/+ mouse,” Cancer Biol. Ther., 5(12):1658-64, dated 2006.
[cited by applicant]
International Preliminary Report on Patentability, issued in International Application No. PCT/US2016/017751, dated Aug. 24, 2017.
[cited by applicant]
Iwamoto et al., “Expression of beta-catenin and full-length APC protein in normal and neoplastic colonic tissues,” Carcinogenesis, 21:1935-40, dated 2000.
[cited by applicant]
Jass et al., “Emerging concepts in colorectal neoplasia,” Gastroenterology, 123:862-876, dated 2002.
[cited by applicant]
Johnson et al. “Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.” British Journal of Cancer 84.10: 1424, dated 2001.
[cited by applicant]
Kawamori, et al., “Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis,” Cancer Research, 58:409-412, dated 1998.
[cited by applicant]
Kelloff et al., “Chemopreventive drug development: perspectives and progress,” Cancer Epidemiology Biomarks and Prevention, 3:85-98, dated 1994.
[cited by applicant]
Kelloff et al., “New agents for cancer chemoprevention,” J. Cell. Biochem., 265:1-28, dated 1996.
[cited by applicant]
Kelloff et al., “Perspectives on chemoprevention agent selection and short term clinical prevention trials,” European J. Cancer Prevention, 5(Supp. 2):79-85, dated 1996.
[cited by applicant]
Kingsnorth et al., “Effects of alpha-difluoromethylornithine and 5-fluorouracil on the proliferation of a human colon adenocarcinoma cell line,” Cancer Res., 43(9):4035-8, dated 1983.
[cited by applicant]
Koomoa, Dana-Lynn T., et al. “DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma.” International Journal of Oncology 42.4: 1219-1228, dated 2013.
[cited by applicant]
Koomoa, Dana.-Lynn T., et al. “Inhibition of S-adenosylmethionine decarboxylase by inhibitor SAM486A connects polyamine metabolism with p53-Mdm2-Akt/protein kinase B regulation and apoptosis in neuroblastoma.” Molecular…
[cited by applicant]
Koomoa, Dana-Lynn T., et al. “Ornithine decarboxylase inhibition by a-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p271Kip1 in neuroblastoma.” Cancer…
[cited by applicant]
Kruh et al., “Expression Pattern of MRP in Human Tissues and Adult Solid Tumor Cell Lines,” J. Natl. Cancer Inst., 87(16):1256-1258, dated 1995.
[cited by applicant]
Ladenheim et al., “Effect of sulindac on sporadic colonic polyps,” Gastroenterology, 108:1083-1087, dated 1995.
[cited by applicant]
Lange, Ingo, et al. “Novel interaction of ornithine decarboxylase with sepiapterin reductase regulates neuroblastoma cell proliferation.” Journal of Molecular Biology 426.2: 332-346, dated 2014.
[cited by applicant]
Lanza et al., “Peptic ulcer and gastrointestinal hemorrhage associated with nonsteroidal anti-inflammatory drug use in patients younger than 65 years. A large health maintenance organization cohort study,” Arch. Intern.…
[cited by applicant]
Le et al., “Effects of socioeconomic status and treatment disparities in colorectal cancer survival,” Cancer Epidemiol. Biomarkers Prev., 17:1950-62, dated 2008.
[cited by applicant]
Levin, Victor A., et al. “Relationship between ornithine decarboxylase levels in anaplastic gliomas and progression-free survival in patients treated with DFMO—PCV chemotherapy.” International journal of cancer 121.10: …
[cited by applicant]
Levin, Victor A., et al. “Phase III randomized study of postradiotherapy chemotherapy with combination a-difluoromethylornithine-PCV versus PCV for anaplastic gliomas.” Clinical Cancer Research 9.3: 981-990, dated 2003.
[cited by applicant]
Levin, Victor A., et al. “Phase III randomized study of postradiotherapy chemotherapy with a-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N′-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glio…
[cited by applicant]
Linsalata et al., “Nutritional factors and polyamine metabolism in colorectal cancer,” Nutrition, 24:382-389, dated 2008.
[cited by applicant]
Lipkin, “New rodent models for studies of chemopreventive agents,” J. Cell Biochem. Suppl., 28-29:144-7, dated 1997.
[cited by applicant]
Love et al., “Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine,” J. Natl. Cancer Inst., 85:732-7, dated 1993.
[cited by applicant]
Lozier et al., “Targeting ornithine decarboxylase reverses the LIN28/Let-7 axis and inhibits glycolytic metabolism in neuroblastoma,” Oncotarget, 6:196-206, dated 2015.
[cited by applicant]
Luk and Baylin, “Ornithine decarboxylase as a biologic marker in familial colonic polyposis,” N. Engl. J. Med., 311(2):80-83, dated 1984.
[cited by applicant]
Lupulescu, “Control of precancer cell transformation into cancer cells: its relevance to cancer prevention,” Cancer Detect. Prev., 20(6):634-637, dated 1996.
[cited by applicant]
Mackenzie, Gerardo G., et al. “Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice.” Cancer prevention research 4.7: 1052-1060, dated 2011.
[cited by applicant]
Martinez et al., “Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene,” Proc. Natl. Acad. Sci. USA, 100:7859-64, dated 2003.
[cited by applicant]
Matsubara et al., “Association between high levels of ornithine decarboxylase activity and favorable prognosis in human colorectal carcinoma,” Clinical Cancer Res., 1:665-71, dated 1995.
[cited by applicant]
McGarrity et al., “Colonic polyamine content and ornithine decarboxylase activity as markers for adenomas,” Cancer, 66:1539-1543, dated 1990.
[cited by applicant]
McLaren et al., “Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas,” Cancer Prev. Res., 1(7):514-21…
[cited by applicant]
Melino, G . . . et al. “Retinoic acid and alpha-difluoromethylornithine induce different expression of neural-specific cell adhesion molecules in differentiating neuroblastoma cells.” Progress in Clinical and Biological…
[cited by applicant]
Melino, Gennaro, Maria Paola Ceru, and Mauro Piacentini. “Correlation between transglutaminase activity and polyamine levels in human neuroblastoma cells: effect of retinoic acid and a-difluoromethylornithine.” Experime…
[cited by applicant]
Meyskens and Gerner, “Development of difluoromethylornithine as a chemoprevention agent for the management of colon cancer,” J. Cell. Biochem., 22:126-131, dated 1995.
[cited by applicant]
Meyskens et al., “Development of difluoromethylornithine (DFMO) as a chemoprevention agent,” Clin. Cancer Res., 5:945-951, dated 1999.
[cited by applicant]
Meyskens et al., “Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial,” Cancer Prev. Res., 1(1):32-8, dated 2008.
[cited by applicant]
Meyskens et al., “Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps,” J. Natl. Cancer Inst., 86(15):1122-1130, dated 1994.
[cited by applicant]
Meyskens et al., “Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention,” J. Natl. Cancer Inst., 90(16):1212-8, dated 1998.
[cited by applicant]
Muscat et al., “Nonsteroidal antiinflammatory drugs and colorectal cancer,” Cancer, 74:1847-1854, drafted 1994.
[cited by applicant]
Nishimura et al., “Independent roles of elF5A and polyamines in cell proliferation,” Biochem. J., 385:779-785, dated 2005.
[cited by applicant]
Norris, M. D. G., et al, “The ornithine decarboxylase G317A polymorphism is prognostic of outcome in primary neuroblastoma and differentially affects promoter binding by the MYCN oncogene.” Advances in Neuroblastoma Res…
[cited by applicant]
O'Brien et al., “Differences in ornithine decarboxylase and androgen receptor allele frequencies among ethnic groups,” Molec. Carcinog., 41(2): 120-3, dated 2004.
[cited by applicant]
Office Communication issued in European Patent Application No. 16749956.5, dated Sep. 12, 2018.
[cited by applicant]
Office Communication issued in U.S. Appl. No. 12/780,592, dated Mar. 20, 2012.
[cited by applicant]
Office Communication issued in U.S. Appl. No. 12/780,592, dated Aug. 14, 2012.
[cited by applicant]
Office Communication issued in U.S. Appl. No. 13/709,753, dated Sep. 10, 2014.
[cited by applicant]
Office Communication issued in U.S. Appl. No. 13/709,753, dated Apr. 21, 2015.
[cited by applicant]
Office Communication issued in U.S. Appl. No. 14/841,750, dated Apr. 21, 2017.
[cited by applicant]
Office Communication issued in U.S. Appl. No. 14/841,750, dated Nov. 24, 2017.
[cited by applicant]
Office Communication issued in U.S. Appl. No. 15/319,857, dated Sep. 13, 2018.
[cited by applicant]
Pardali and Moustakas, “Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer,” Biochimica et Biophysica Acta, 1775:21-62, dated 2007.
[cited by applicant]
Pasricha et al., “The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis,” Gastroenterology, 109:994-998, dated 1995.
[cited by applicant]
Paz et al., “Plyamines are oncometabolites that regulate the LIN28/let-7 pathway in colorectal cancer cells,” Molecular Carcinogensis, dated 2013.
[cited by applicant]
PCT International Search Report and Written Opinion, issued in International application No. PCT/US10/34974, dated Jul. 2, 2010.
[cited by applicant]
PCT International Search Report and Written Opinion, issued in International Application No. PCT/US2014/042979, dated Jan. 29, 2015.
[cited by applicant]
PCT International Search Report and Written Opinion, issued in International Application No. PCT/US2016/017751, dated Jul. 14, 2016.
[cited by applicant]
Peel et al., “Characterization of hereditary nonpolyposis colorectal cancer families from a population-based series of cases,” J. Natl. Cancer Inst., 92:1517-22, dated 2000.
[cited by applicant]
Pegg, “Recent advances in the biochemistry of polyamines in eukaryotes,” Biochem., 234(2):249-262, dated 1986.
[cited by applicant]
Piazza et al., “Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis,” Cancer Res., (55):3110-3116, dated 1995.
[cited by applicant]
Piazza et al., “Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction,”…
[cited by applicant]
Piazza et al., “Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels,” Cancer Res., (57):2909-2915, dated 1997.
[cited by applicant]
Pollard and Luckert, “Prevention and treatment of primary intestinal tumors in rats by piroxicam,” Cancer Res., 49:6471-6473, dated 1989.
[cited by applicant]
Porter et al., “Polyamine biosynthetic activity in normal and neoplastic human colorectal tissue,” Cancer, 60:1275-1281, dated 1987.
[cited by applicant]
Prieto, Jenaro Garcia-Huidobro. “Molecular and Functional Consequences of Gentic Variability in the Ornithine Decarboxylase Gene in Colorectal Cancer.” 2013.
[cited by applicant]
Pugh, Trevor J. et al. “The genetic landscape of high-risk neuroblastoma.” Nature Genetics 45.3: 279, dated 2013.
[cited by applicant]
Quemener et al., “Polyamine deprivation: a new tool in cancer treatment”, Institute of Anticancer Research, 14:443-448, dated 1994.
[cited by applicant]
Raj et al., “Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas”, British Journal of Cancer, 108(3):512-518, dated 2013.
[cited by applicant]
Reddy et al., “Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in die…
[cited by applicant]
Reddy et al., “Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development,” Cancer Res., 47:5340-5346, dated 1987.
[cited by applicant]
Rial, Nathaniel S., Frank L. Meyskens, and Eugene W. Gerner. “Polyamines as mediators of APC-dependent intestinal carcinogenesis and cancer chemoprevention.” Essays in Biochemistry 46: 111-124, dated 2009.
[cited by applicant]
Roberts and Wakefield, “The two faces of transforming growth factor beta in carcinogenesis,” Proc. Natl. Acad. Sci. USA, 100:8621-3, dated 2003.
[cited by applicant]
Rounbehler et al., “Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma,” Cancer Res., 69:547-553, dated 2009.
[cited by applicant]
Saletta et al., “Molecular profiling of childhood cancer: Biomarkers and novel therapies,” BBA Clinical, 1:59-77, dated 2014.
[cited by applicant]
Samaha et al., “Modulation of apopotsosi by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate, apoptotic index as a biomarker in colon cancer chemoprevention and promotion,” Cancer Res.,…
[cited by applicant]
Samal, Katherine, et al. “AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport.” Interna…
[cited by applicant]
Sausville, Edward A., and Angelika M. Burger. “Contributions of human tumor xenografts to anticancer drug development.” Cancer Research 66.7: 3351-3354, dated 2006.
[cited by applicant]
Seiler and Knodgen, “High-performance liquid chromatographic procedure for the simultaneous determination of the natural polyamines and their monoacetyl derivatives,” J. Chromatogr., 221(2):227-235, dated 1980.
[cited by applicant]
Seiler et al., “Endogenous and exogenous polyamines in support of tumor growth”, Cancer Research, 50:5077-5083, dated 1990.
[cited by applicant]
Sholler et al., [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr LB-179. doi:10.11…
[cited by applicant]
Sholler, Giselle L. Saulnier, et al. “A phase I trial of DFMO targeting polyamine addiction in patients with relapsed/refractorr neuroblastoma.” PLoS One 10.5: e0127246, dated 2015.
[cited by applicant]
Silva et al., “Role of peripheral polyamines in the development of inflammatory pain,” Biochemical Pharmacology, 82:269-277, dated 2011.
[cited by applicant]
Simoneau et al., “Alpha-difluoromethylornithine and polyamine levels in the human prostate: results of a phase IIa trial,” J. Natl. Cancer Inst., 93:57-9, dated 2001.
[cited by applicant]
Simoneau et al., “The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial,” Cancer Epidemiol. Biomark…
[cited by applicant]
Singh and Reddy, “Molecular markers in chemoprevention of colon cancer. Inhibition of expression of ras-p21 and p53 by sulindac during azoxymethane-induced colon carcinogenesis,” Annals. NY Acad. Sci., (768):205-209, da…
[cited by applicant]
Scholler et al., Abstract LB-179: Phase I trial of relapsed neuroblastoma with DFMO alone and in combination with etoposide, American Association for Cancer Research, vol. 73, Issue 8 Suppl., 4 pages, dated Apr. 2013.
[cited by applicant]
Scholler et al., A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma, PLoS One, 20 pages, dated May 27, 2015.
[cited by applicant]
Lozier et al., Targeting ornithine decarboxylase reverses the LIN28/Let-7 axis and inhibits glycolytic metabolism in neuroblastoma, Oncotarget, vol. 6, No. 1, 196-206, 11 pages, dated Nov. 15, 2014.
[cited by applicant]
Evageliou and Hogarty, Disrupting Polyamine Homeostasis as a Therapeutic Strategy for Neuroblastoma, Clin Cancer Res 2009;15(19), 7 pages, dated Oct. 1, 2009.
[cited by applicant]
Gamble et al., Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma, Frontiers in Oncology, vol. 2, Article 162, 10 pages, date Nov. 16, 2012.
[cited by applicant]
Hogarty et al., ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma, Cancer Res; 68(23): 9735-9745, 25 pages, dated Dec. 1, 2008.
[cited by applicant]
Meyskens and Gerner, Development of Difluoromethylornithine (DFMO) as a Chemoprevention Agent, Clinical Cancer Research, vol. 6, 945-951, 8 pages, dated May 1999.
[cited by applicant]
Rounbehler et al., Targeting Ornithine Decarboxylase Impairs Development of MYCN-Amplified Neuroblastoma, Cancer Res 2009; 69: (2), 8 pages, dated Jan. 15, 2009.
[cited by applicant]
Zell et al., Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival, Clin Cancer Res.; 15(19): 6208-621, 20 pages, dated Oct. 1, 2009.
[cited by applicant]
VANIQATM Label, 10 pages, dated Jul. 27, 2000.
[cited by applicant]
Johansson et al., J. of Pharmacokinetics and Pharmacodynamics, vol. 40, pp. 117-128, dated 2013.
[cited by applicant]
Bachmann, Abstract LB-179: Phase I Trial of Relapsed Neuroblastoma with DFMO Alone and in Combination with Etoposide, vol. 73, Supplement 8, LB-179, Apr. 15, 2013, dated Apr. 15, 2015.
[cited by applicant]
“NCT01245816” retrieved from clinicaltrials.gov archive on Jan. 20, 2017, dated Apr. 23, 2015.
[cited by applicant]
“NCT01483144” retrieved from clinicaltrials.gov archive on Jan. 20, 2017, dated Jul. 28, 2015.
[cited by applicant]
“VANIQA” (eflornithine hydrochloride) Prescription Information, dated Jul. 2010.
[cited by applicant]
Alberts et al., Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase?, J. Cell. Biochem. Supp., (22): 18-23, dated 1995.
[cited by applicant]
Arber et al., “A K-ras oncogene increases resistance to sulindac-induces apoptosis in rat enterocytes,” Gastroenterology, 113: 1892-1990, dated 1997.
[cited by applicant]
Babbar et al., “Induction of spermidine/spermine N1-acetyltransferase (SSAT) by aspirin in Caco-2 colon cancer cells,” Biochem. J., 394:317-24, dated 2006.
[cited by applicant]
Bachmann, Andre S., Dirk Geerts, and Giselle L. Saulnier Sholler. “Neuroblastoma: Ornithine decarboxylase and polyamines are novel targets for therapeutic intervention.” Neuroblastoma. Springer, Dordrecht, 91-103, dated…
[cited by applicant]
Bachrach et al., “Polyamines: new cues in cellular signal transduction,” News Physiol. Sci., 16:106-109, dated 2001.
[cited by applicant]
Barry et al., “Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention,” J. Natl. Cancer Inst., 98(20):1494-500, dated 2006.
[cited by applicant]
Basuroy and Gerner, “Emerging concepts in targeting the polyamine metabolic pathway in epithelial cancer chemoprevention and chemotherapy,” J. Biochem., 139:27-33, dated 2006.
[cited by applicant]
Bedi et al., “Inhibition of apoptosis during development of colorectal cancer,” Cancer Res., 55(9):1811-1816, dated 1995.
[cited by applicant]
Bello-Fernandez et al., “The ornithine decarboxylase gene is a transcriptional target of c-Myc,” Proc. Natl. Acad. Sci. USA, 90:7804-8, dated 1993.
[cited by applicant]
Boolbol, et al., “Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis,” Cancer Research, 56:2556-2560, dated 1996.
[cited by applicant]
Boone et al., “Biomarker end-points in cancer chemoprevention trails,” IARC Scientific Publications, 142:273-280, dated 1997.
[cited by applicant]
Bosslet, K., et al. “Monoclonal antibodies against epitopes on ganglioside GD 2 and its lactones.” Cancer Immunology, Immunotherapy 29.3: 171-178 1989.
[cited by applicant]
Boyle et al., “Polyamine contents in rectal and buccal mucosae in humans treated with oral difluoromethylornithine,” Cancer Epidemiol. Biomarkers Prev., 1:131-135, dated 1992.
[cited by applicant]
Brabender et al., “Upregulation of ornithine decarboxylase mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma,” J. Gastrointest. Surg., 5:174-181; discussion 182, dated 2001.
[cited by applicant]
Braverman et al., “Ornithine decarboxylase: an unreliable marker for the identification of population groups at risk for colonic neoplasia,” Am. J. Gastronenterology, 85:723-726, dated 1990.
[cited by applicant]
Castel et al., “Treatment of high-risk neuroblastoma with anti-GD2 antibodies,” Clinical and Translational Oncology, 12:788-793, dated 2010.
[cited by applicant]
Chapman, Sharon K. “Antitumor effects of vitamin A and inhibitors of ornithine decarboxylase in cultured neuroblastoma and glioma cells.” Life Sciences 26.16: 1359-1366, dated 1980.
[cited by applicant]
Chen, Kuang Yu, David Nau, and Alice YC Liu. “Effects of inhibitors of ornithine decarboxylase on the differentiation of mouse neuroblastoma cells.” Cancer Research 43.6: 2812-2818, dated 1983.
[cited by applicant]
Cheung; N. K., et al. “3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study.” International Journal of Oncology 12.6: 1299-1605, dated 1998.
[cited by applicant]
Childs et al., “Polyamine-dependent gene expression,” Cell. Molec. Life Sci., 60:1394-1406, dated 2003.
[cited by applicant]
Choi, Peter S., Yulin Li, and Dean W. Felsher. “Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistance.” Proceedings of the National Academy of Sciences 111.32: E3316-E3324, …
[cited by applicant]
Croghan et al., “Dose-related alpha-difluoromethylornithine ototoxicity,” Am. J. Clin. Oncol., (14):331-5, dated 1991.
[cited by applicant]
Derynck et al., “TGF-beta signaling in tumor suppression and cancer progression,” Nature Genetics, 29:117-29, dated 2001.
[cited by applicant]
DuBois et al., “G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2,” Cancer Res., 56:733-737, dated 1996.
[cited by applicant]
Erdman et al., “Assessment of Mutations in Ki-ras and P53 in colon cancers from azoxymethane- and dimethylhydrazine-treated rats,” Mol. Carcin., (19):137-144, dated 1997.
[cited by applicant]
Erdman et al., “APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse,” Carcinogenesis, 20(9):1709-13, dated 1999.
[cited by applicant]
Ernestus, R. I., et al. “Polyamine metabolism in brain tumours: diagnostic relevance of quantitative biochemistry.” Journal of Neurology, Neurosurgery & Psychiatry 71.1: 88-92, dated 2001.
[cited by applicant]
Evageliou, Nicholas F., and Michael D. Hogarty. “Disrupting polyamine homeostasis as a therapeutic strategy for neuroblastoma.” Clinical Cancer Research 15.19: 5956-5961, dated 2009.
[cited by applicant]
Fearon et al., “A genetic model for colorectal tumorigenesis,” Cell, 61:759-767, dated 1990.
[cited by applicant]
Fultz and Gerner, “APC-dependent regulation of ornithine decarboxylase in human colon tumor cells,” Mol. Carcinog., 34:10-8, dated 2002.
[cited by applicant]
Gamble et al., “Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma,” Frontier in Oncology, 2(162):1-10, dated 2012.
[cited by applicant]
Gann et al., “Low-dose aspirin and incidence of colorectal tumors in a randomized trial,” J. Natl. Cancer Inst., 85:1220-1224, dated 1993.
[cited by applicant]
Geerts, Dirk, et al. “The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification.” International Journal of Cancer 126.9: 2012…
[cited by applicant]
Gerner and Meyskens, “Polyamines and cancer: old molecules, new understanding,” Nature Rev. Cancer, 4:781-92, dated 2004.
[cited by applicant]
Gerner et al., “Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation,” Clinical Cancer Research, 15(3):758-761, dated 2009.
[cited by applicant]
Singh et al., “Bifidobacterium longum, a lactic acid-producing intestinal bacterium inhibits colon cancer and modulates the intermediate biomarkers of colon carcinogenesis,” Carcinogenesis, 18:833-841, dated 1997.
[cited by applicant]
Singh et al., “Modulation of azoxymethane-induced mutational activation of ras protooncogenes by chemopreventive agents in colon carcinogenesis,” Carcinogenesis, (15):1317-1323, dated 1994.
[cited by applicant]
Smithson et al., “Discovery of potent and selective inhibitors of Trypanosoma brucei ornithine decarboxylase,” The Journal of Biological Chemistry, 265(22):16771-16781, dated 2010.
[cited by applicant]
Soda et al., “Polyamine-rich food decreases age-associated pathology and mortality in aged mice,” Experimental Gerontology, 44: 727-732, dated 2009.
[cited by applicant]
Su et al., “Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene,” Science, (256):668-670, dated 1992.
[cited by applicant]
Tabib et al., “Role of polyamines in mediating malignant transformation and oncogene expression,” Int. J. Biochem. Cell. Biol., 31:1289-1295, dated 1999.
[cited by applicant]
Tempero et al., “Chemoprevention of mouse colon tumors with difluoromethylornithine during and after carcinogen treatment,” Cancer Res., 49(21):5793-7, dated 1989.
[cited by applicant]
Third Party Observation, submitted in International Application No. PCT/US2016/017751, dated May 16, 2017.
[cited by applicant]
Thomas and Thomas, “Polyamine metabolism and cancer,” J. Cell Mol. Med., 7:113-26, dated 2003.
[cited by applicant]
Thompson et al., “Inhibition of mammary carcinogenesis by sulfone metabolite of sulindac,” J. Natl. Cancer Inst., (87):125-1260, dated 1995.
[cited by applicant]
Thompson et al., “Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma,” Gastroenterology, 139(3): 797-805, dated 2010.
[cited by applicant]
Thompson, et al., “Sulfone metabolite of sulindac inhibits mammary carcinogenesis,” Cancer Research, 57:267-271, dated 1997.
[cited by applicant]
Vane and Botting, “Mechanism of action of anti-inflammatory drugs,” Scand. J. Rheumatol., 25(Suppl. 102):9-21, dated 1996.
[cited by applicant]
Vargas et al., “Dietary Polyamine intake and polyamines measured in urine,” Nutrition and Cancer, 66(7): 1144-1153, dated 2014.
[cited by applicant]
Visvanathan et al., “Association among an ornithine decarboxylase polymorphism, androgen receptor gene (CAG) repeat length and prostate cancer risk,” J. Urol., 171(2 Pt 1): 652-5, dated 2004.
[cited by applicant]
Wallace and Caslake, “Polyamines and colon cancer,” Eur J Gastroenterol Helatol., 13(9): 1033-1039, dated 2001.
[cited by applicant]
Wallace, “The physiological role of the polyamines,” Eur. J. Clin. Invest., 30:1-3, dated 2000.
[cited by applicant]
Wang et al., “Mucosal polyamine measurements and colorectal cancer risk,” J. Cell. Biochem., 63:252-257, dated 1996.
[cited by applicant]
Yu, Alice L., et al. “Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.” New England Journal of Medicine 363.14: 1324-1334, dated 2010.
[cited by applicant]
Zell et al., “Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival,” Clin. Cancer Res., 15(19):6208-16, dated 2009.
[cited by applicant]
Zell et al., “Ornithine decarboxylase (Odc)-1 gene polymorphism effects on baseline tissue polyamine levels and adenoma recurrence in a randomized phase III adenoma prevention trial of DFMO + sulindac versus placebo,” J…
[cited by applicant]
Zell et al., “Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients,” J. Natl. Cancer Inst., 102:1513-1516, dated 2010.
[cited by applicant]
Zell et al., “Risk and risk reduction involving arginine intake and meat consumption in colorectal tumorigenesis and survival,” Intl. J. Cancer, 120:459-68, dated 2007.
[cited by applicant]
Zell et al., “Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas,” Cancer Prev. Res., 2(3):20…
[cited by applicant]
Zell et al., “Survival after colorectal cancer diagnosis is associated with colorectal cancer family history,” Cancer Epidemiol. Biomarkers Prev., 17:3134-40, dated 2008.
[cited by applicant]
Zeng, G. X., et al. “New concept and clinical application of colorectal intraepithelial neoplasia and carcinoma.” Zhonghua wai ke za zhi [Chinese Journal of Surgery] 45.7: 449-451, dated 2007.
[cited by applicant]
Ziogas and Anton-Culver, “Validation of family history data in cancer family registries,” Am. J. Prev. Med., 24:190-8, dated 2003.
[cited by applicant]
Zoumas-Morse et al., “Development of a polyamine database for assessing dietary intake,” J. Am. Diet. Assoc., 107:1024-1027, dated 2007.
[cited by applicant]
Office Communication issued in Japanese Patent Application No. 2017-560893, mailed Dec. 2, 2019, dated Dec. 2, 2019.
[cited by applicant]
Jacob, Jeffrey, United States Securities and Exchange Commission, Cancer Prevention Pharamaceuticals, Inc., 215 pages, dated 2015.
[cited by applicant]
Yu, Alice L., et al., Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma, N Engl J Med., 363(14): 1324-1334, 18 pages, dated Sep. 30, 2010.
[cited by applicant]
Simon, Thorsten, et al., Long Term Outcome of High-Risk Neuroblastoma Patients After Immunotherapy with Antibody Ch14.18 or oral Metronomic Chemotherapy, BMC Cancer 2011, 8 pages, dated 2011.
[cited by applicant]
Matthay, Katherine K., Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-CIS-Retinoic Acid, The New England Journal of Medicine, vol. 341, No.…
[cited by applicant]
Smith, Valeria et al., High-Risk Neuroblastoma Treatment Review, Children MDPI Journal, 7 pages, dated Aug. 28, 2018.
[cited by applicant]
Monclair, Tom et al., The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report, Journal of Clinical Oncology, vol. 27, No. 2, 6 pages, dated Jan. 10, 2009.
[cited by applicant]
Cohn, Susan L., et al., The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report, Journal of Clinical Oncology, vol. 27, No. 2, 9 pages, dated Jan. 10, 2009.
[cited by applicant]
Sholler, Giselle L. Saulnier, et al., A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma, Supplemental S1 Table Enrollment Characteristics and Previous Relapse Thera…
[cited by applicant]
Oesterheld, Javier, et al., Eflornithine as Postimmunotherapy Maintenance in High-Rish Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons, ASCO Journal of Clinical Oncology, 14 p…
[cited by applicant]
Simoneau, Anne R., et al., The Effect of Difluoromethylornithine on Decreasing Prostate Size and Polyamines in Men: Results of a Year-Long Phase IIb Randomized Placebo-Controlled Chemoprevention Trial, Cancer Epidemiol …
[cited by applicant]
Meyskens, Frank L., et al., Effect of a-Difluoromethylornithine on Rectal Mucosal Levels of Polyamines in a Randomized, Double-Blinded Trial for Colon Cancer Prevention, Journal of the National Cancer Institute, vol. 90…
[cited by applicant]
Meyskens, Frank L. Jr., et al., Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial, Cancer Prev Res, 14 pages, dated Jun. 1, 200…
[cited by applicant]
Carbone, Paul P., Phase I Chemoprevention Study of Difluoromethylornithine in Subjects with Organ Transplants, Cancer Epidemiology, Biomarkers & Prevention, vol. 10, 657-661, dated Jun. 2001.
[cited by applicant]
Sinicrope, Frank A., et al., “Evaluation of Difluoromethylornithine for the Chemoprevention of Barrett's Esophagus and Mucosal Dysplasia,” American Associated for Cancer Research, 11 pages, dated Jun. 2011.
[cited by applicant]
Yu, Alice L., et al., Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma, The New England Journal of Medicine, 11 pages, dated Sep. 30, 2010.
[cited by applicant]
Thomas, David W., Clinical Development Success Rates 2006-2015, 28 pages, dated 2016.
[cited by applicant]
Lewis, Elizabeth C., et al., A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma, Int. J. Cancer, 3152-3159, dated Apr. 23, 2020.
[cited by applicant]
Sandler, Robert S., et al., Rectal Mucosal Ornithine Decarboxylase Activity is Not a Useful Marker of Risk for Colorectal Neoplasia, Digestive Diseases and Sciences, vol. 37, No. 11, pp. 1718-1724, dated Nov. 1992.
[cited by applicant]
Desai, Tusar K., et al., Failure of Rectal Ornithine Decarboxylase to Identify Adenomatous Polyp Status, American Gastroenterological Association, pp. 1562-1567, dated Nov. 1992.
[cited by applicant]
Abeloff, Martin D., et al., Phase II Trials of a-Difluoromethylornithine, an Inhibitor of Polyamine Synthesis in Advanced Small Cell Lung Cancer and Colon Cancer, Cancer Treatment Reports, vol. 70, No. 7, 3 pages, dated…
[cited by applicant]
Prados, Michael D., et al., Phase III Trial of Accelerated Hyperfractionation With or Without Difluromethylornithine (DFMO) Versus Standard Fractionated Radiotherapy With or Without DFMO for Newly Diagnosed Patients Wit…
[cited by applicant]
Fabian, Carol J., et al., A Phase II Breast Cancer Chemoprevention Trial of Oral-Difluoromethylornithine: Breast Tissue, Imaging, and Serum and Urine Biomarkers, Clinical Cancer Research, vol. 8, 3105-2117, dated Oct. 2…
[cited by applicant]
Vlastos, Anne-Therese, et al., Results of a Phase II Double-Blinded Randomized Clinical Trial of Difluoromethylornithine for Cervical Intraepithelial Neoplasia Grades 2 to 3, Clinical Cancer Research, vol. 11, 390-396, …
[cited by applicant]
Malki, Ahmed, et al., Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements, International Journal of Molecular Sciences, 24 pages, dated Dec. 24, 2020.
[cited by applicant]
Messing, Edward, et al., Randomized Prospective Phase III Trial of Difluoromethylornithine vs Placebo in Preventing Recurrence of Completely Resected Low Risk Superficial Bladder Cancer, The Journal of Urology, vol. 176…
[cited by applicant]
Sholler, Giselle L Saulnier et al., Maintenance DFMO Increases Survival in High Risk Neuroblastoma, Scientific Reports, 10 pages, dated Sep. 27, 2018.
[cited by applicant]
Pearson, Andrew, et al., High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial, Lancet Oncol, vol. 9, 10 pages, dated Mar. 2008.
[cited by applicant]